Corvus Pharmaceuticals, Inc. (CRVS) Stock Price

CRVSStock
$14.56+153.87%52W
Market Cap$1.22B
P/E
PEG Ratio
Div yield
Beta1.49

CRVS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-33.36%
Price vs S&P 500 (4W)2.81%
VGM Score57.88

CRVS Earnings Surprise History

Q2 25-0.13est. -0.12
Q3 25-0.12est. -0.14
Q4 25-0.15est. -0.13
Q1 26-0.15est. -0.15
Q2 26-0.19est. -0.17

CRVS Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.23
4.23
4.23
4.29

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
CRVSCorvus Pharmaceuticals, Inc.
C$14.56
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing immunotherapies that target proteins critical to T cell function and activation. Its lead candidate, soquelitinib, is designed to inhibit ITK to modulate T cell responses in immune-mediated disorders. The company also develops Ciforadenant and Mupadolimab, addressing complementary immune-regulation pathways.